Nov252020 Anavex Life Sciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference November 25, 2020
Aug62020 Anavex Life Sciences Reports Fiscal 2020 Third Quarter Financial Results And Provides Business Updates August 6, 2020
Aug52020 Anavex Life Sciences Receives TGA Special Access Scheme Approval for ANAVEX®2-73 (blarcamesine) for Alzheimer’s Disease Patients August 5, 2020
Aug42020 Anavex Life Sciences to Announce Fiscal 2020 Third Quarter Financial Results on Thursday, August 6th, 2020 August 4, 2020
Dec102019 Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019 December 10, 2019
Sep272019 Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 Study September 27, 2019
Sep182019 Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference September 18, 2019
Jul292019 Anavex Life Sciences Receives Positive Opinion for Orphan Designation from the European Medicines Agency for ANAVEX®2-73 for the Treatment of Rett Syndrome July 29, 2019
Apr52019 Anavex Life Sciences to Present at the H.C. Wainwright Annual Global Life Sciences Conference April 5, 2019
Mar182019 Anavex Life Sciences Announces First Patient Dosed in Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Rett Syndrome in the U.S. March 18, 2019
Feb72019 Anavex Life Sciences Reports Fiscal 2019 First Quarter Financial Results And Provides Clinical Study Updates February 7, 2019
